BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sterling RK, Jeffers L, Gordon F, Venook AP, Reddy KR, Satomura S, Kanke F, Schwartz ME, Sherman M. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2009;7:104-113. [PMID: 18849011 DOI: 10.1016/j.cgh.2008.08.041] [Cited by in Crossref: 93] [Cited by in F6Publishing: 78] [Article Influence: 6.6] [Reference Citation Analysis]
Number Citing Articles
1 Liu XN, Cui DN, Li YF, Liu YH, Liu G, Liu L. Multiple “Omics” data-based biomarker screening for hepatocellular carcinoma diagnosis. World J Gastroenterol 2019; 25(30): 4199-4212 [PMID: 31435173 DOI: 10.3748/wjg.v25.i30.4199] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
2 Rich N, Singal AG. Hepatocellular carcinoma tumour markers: current role and expectations. Best Pract Res Clin Gastroenterol. 2014;28:843-853. [PMID: 25260312 DOI: 10.1016/j.bpg.2014.07.018] [Cited by in Crossref: 59] [Cited by in F6Publishing: 63] [Article Influence: 7.4] [Reference Citation Analysis]
3 Maida M, Malizia G, Affronti A, Virdone R, Maida C, Margherita V, D’amico G. Screening and surveillance for hepatocellular carcinoma: perspective of a new era? Expert Review of Anticancer Therapy 2016;16:1291-302. [DOI: 10.1080/14737140.2016.1246965] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
4 Fatima S, Luk JM, Poon RT, Lee NP. Dysregulated expression of dickkopfs for potential detection of hepatocellular carcinoma. Expert Rev Mol Diagn 2014;14:535-48. [PMID: 24809435 DOI: 10.1586/14737159.2014.915747] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
5 Bruix J, Reig M, Sherman M. Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology. 2016;150:835-853. [PMID: 26795574 DOI: 10.1053/j.gastro.2015.12.041] [Cited by in Crossref: 781] [Cited by in F6Publishing: 771] [Article Influence: 130.2] [Reference Citation Analysis]
6 Kondo Y, Kimura O, Shimosegawa T. Significant biomarkers for the management of hepatocellular carcinoma. Clin J Gastroenterol 2015;8:109-15. [PMID: 25855582 DOI: 10.1007/s12328-015-0568-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
7 Mohamed RA, Maghraby HM, Abd El Salam EM, Nageb HM, Ahmad EE, Mohamed NA. Evaluation of serum endoglin as noninvasive marker in hepatocellular carcinoma. Egypt J Intern Med 2015;27:15-20. [DOI: 10.4103/1110-7782.155832] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
8 Sharma BK, Srinivasan R, Kapil S, Singla B, Saini N, Chawla YK, Chakraborti A, Duseja A, Kalra N, Dhiman RK. Serum levels of angiogenic and anti-angiogenic factors: their prognostic relevance in locally advanced hepatocellular carcinoma. Mol Cell Biochem 2013;383:103-12. [PMID: 23912396 DOI: 10.1007/s11010-013-1759-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
9 Tsuchiya N, Sawada Y, Endo I, Saito K, Uemura Y, Nakatsura T. Biomarkers for the early diagnosis of hepatocellular carcinoma. World J Gastroenterol 2015; 21(37): 10573-10583 [PMID: 26457017 DOI: 10.3748/wjg.v21.i37.10573] [Cited by in CrossRef: 235] [Cited by in F6Publishing: 222] [Article Influence: 33.6] [Reference Citation Analysis]
10 Sturgeon CM, Duffy MJ, Hofmann BR, Lamerz R, Fritsche HA, Gaarenstroom K, Bonfrer J, Ecke TH, Grossman HB, Hayes P, Hoffmann RT, Lerner SP, Löhe F, Louhimo J, Sawczuk I, Taketa K, Diamandis EP; National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem 2010;56:e1-48. [PMID: 20207771 DOI: 10.1373/clinchem.2009.133124] [Cited by in Crossref: 146] [Cited by in F6Publishing: 119] [Article Influence: 12.2] [Reference Citation Analysis]
11 Li GJ, Chen QY, Harrison TJ, Wang XY, Hu LP, Yang QL, Li KW, Fang ZL. Des-γ carboxyprothrombin may not be a good biomarker for hepatocellular carcinoma in those chronically infected with hepatitis B virus with basal core promoter double mutations (T^{1762}, A^{1764}), a prospective study. Cancer Biomark 2017;18:241-8. [PMID: 28085009 DOI: 10.3233/CBM-160131] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
12 Behne T, Copur MS. Biomarkers for hepatocellular carcinoma. Int J Hepatol 2012;2012:859076. [PMID: 22655201 DOI: 10.1155/2012/859076] [Cited by in Crossref: 53] [Cited by in F6Publishing: 60] [Article Influence: 5.3] [Reference Citation Analysis]
13 Lee NE, Kim SH, Yu DY, Woo EJ, Kim MI, Seong GS, Lee SM, Ko JH, Kim YS. Aglycosylated antibody-producing mice for aglycosylated antibody-lectin coupled immunoassay for the quantification of tumor markers (ALIQUAT). Commun Biol 2020;3:636. [PMID: 33128033 DOI: 10.1038/s42003-020-01363-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Frankul L, Frenette C. Hepatocellular Carcinoma: Downstaging to Liver Transplantation as Curative Therapy. J Clin Transl Hepatol. 2021;9:220-226. [PMID: 34007804 DOI: 10.14218/jcth.2020.00037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Guan MC, Ouyang W, Liu SY, Sun LY, Chen WY, Tong XM, Zhu H, Yang T. Alpha-fetoprotein, protein induced by vitamin K absence or antagonist-II, lens culinaris agglutinin-reactive fraction of alpha-fetoprotein alone and in combination for early detection of hepatocellular carcinoma from nonalcoholic fatty liver disease: A multicenter analysis. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00121-7. [PMID: 35643910 DOI: 10.1016/j.hbpd.2022.05.003] [Reference Citation Analysis]
16 Morimoto M, Numata K, Nozaki A, Kondo M, Moriya S, Taguri M, Morita S, Konno M, Sugo A, Miyajima E, Maeda S, Tanaka K. Novel Lens culinaris agglutinin-reactive fraction of α-fetoprotein: a biomarker of hepatocellular carcinoma recurrence in patients with low α-fetoprotein concentrations. Int J Clin Oncol 2012;17:373-9. [PMID: 21847534 DOI: 10.1007/s10147-011-0306-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
17 Nouso K, Kobayashi Y, Nakamura S, Kobayashi S, Takayama H, Toshimori J, Kuwaki K, Hagihara H, Onishi H, Miyake Y. Prognostic importance of fucosylated alpha-fetoprotein in hepatocellular carcinoma patients with low alpha-fetoprotein. J Gastroenterol Hepatol. 2011;26:1195-1200. [PMID: 21410750 DOI: 10.1111/j.1440-1746.2011.06720.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
18 Lee JH, Cho CH, Kim SH, Kang JG, Yoo JS, Chang CL, Ko JH, Kim YS. Semi-quantitative measurement of a specific glycoform using a DNA-tagged antibody and lectin affinity chromatography for glyco-biomarker development. Mol Cell Proteomics 2015;14:782-95. [PMID: 25525205 DOI: 10.1074/mcp.O114.043117] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
19 Omran MM, Farid K, Omar MA, Emran TM, El-Taweel FM, Tabll AA. A combination of α-fetoprotein, midkine, thioredoxin and a metabolite for predicting hepatocellular carcinoma. Ann Hepatol 2020;19:179-85. [PMID: 31648804 DOI: 10.1016/j.aohep.2019.09.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
20 Xing H, Zheng YJ, Han J, Zhang H, Li ZL, Lau WY, Shen F, Yang T. Protein induced by vitamin K absence or antagonist-II versus alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: A systematic review with meta-analysis. Hepatobiliary Pancreat Dis Int. 2018;17:487-495. [PMID: 30257796 DOI: 10.1016/j.hbpd.2018.09.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
21 Mendizabal M, Reddy KR. Current Management of Hepatocellular Carcinoma. Medical Clinics of North America 2009;93:885-900. [DOI: 10.1016/j.mcna.2009.03.004] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 3.4] [Reference Citation Analysis]
22 Tanaka T, Taniguchi T, Sannomiya K, Takenaka H, Tomonari T, Okamoto K, Kitamura S, Okahisa T, Tamaki K, Mikasa H, Suzuki S, Takayama T. Novel des-γ-carboxy prothrombin in serum for the diagnosis of hepatocellular carcinoma. J Gastroenterol Hepatol 2013;28:1348-55. [PMID: 23432345 DOI: 10.1111/jgh.12166] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
23 Tampaki M, Doumba PP, Deutsch M, Koskinas J. Circulating biomarkers of hepatocellular carcinoma response after locoregional treatments: New insights. World J Hepatol 2015; 7(14): 1834-1842 [PMID: 26207165 DOI: 10.4254/wjh.v7.i14.1834] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
24 Chen S, Li J, Tan X, Xu Q, Mo Y, Qin H, Zhou L, Ma L, Wei Z. Clinical role of combining alpha-fetoprotein and lens culinaris agglutinin-reactive fraction of alpha-fetoprotein for hepatocellular carcinoma: Evidence from literature and an original study. J Clin Lab Anal 2020;34:e23262. [PMID: 32167614 DOI: 10.1002/jcla.23262] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
25 Chen J, Wu G, Li Y. Evaluation of Serum Des-Gamma-Carboxy Prothrombin for the Diagnosis of Hepatitis B Virus-Related Hepatocellular Carcinoma: A Meta-Analysis. Dis Markers. 2018;2018:8906023. [PMID: 30402170 DOI: 10.1155/2018/8906023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
26 Attallah AM, Omran MM, Attallah AA, Abdallah SO, Farid K, Darwish H, El-Dosoky I, Shaker YM. HCC-ART score, a simple, highly sensitive and specific test for early diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Br J Cancer 2013;109:1657-65. [PMID: 23982602 DOI: 10.1038/bjc.2013.481] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
27 De J, Shen Y, Qin J, Feng L, Wang Y, Yang L. A Systematic Review of Des-γ-Carboxy Prothrombin for the Diagnosis of Primary Hepatocellular Carcinoma. Medicine (Baltimore). 2016;95:e3448. [PMID: 27124038 DOI: 10.1097/md.0000000000003448] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS. Hepatocellualar carcinoma serum markers. Semin Oncol. 2012;39:410-433. [PMID: 22846859 DOI: 10.1053/j.seminoncol.2012.05.001] [Cited by in Crossref: 103] [Cited by in F6Publishing: 101] [Article Influence: 10.3] [Reference Citation Analysis]
29 Dufour DR. Liver Disease. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Elsevier; 2012. pp. 1637-93. [DOI: 10.1016/b978-1-4160-6164-9.00050-0] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
30 Gurakar A, Ma M, Garonzik-wang J, Kim A, Anders RA, Oshima K, Georgiades C, Gurakar M, Ottmann S, Cameron AM, Philosophe B, Saberi B. Clinicopathological Distinction of Low-AFP-Secreting vs. High-AFP-Secreting Hepatocellular Carcinomas. Annals of Hepatology 2018;17:1052-66. [DOI: 10.5604/01.3001.0012.7206] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
31 Sherman M. Limitations of screening for hepatocellular carcinoma. Hepat Oncol 2014;1:161-3. [PMID: 30190948 DOI: 10.2217/hep.13.22] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
32 Zhang Y, Xi Y, Fang J, Luo S, Wilson JJ, Huang RP. Identification and characterization of monoclonal antibodies against GP73 for use as a potential biomarker in liver cancer screening and diagnosis. J Immunoassay Immunochem 2016;37:390-406. [PMID: 27088654 DOI: 10.1080/15321819.2016.1154866] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
33 Attallah AM, El-far M, Omran MM, Abdelrazek MA, Attallah AA, Saeed AM, Farid K. GPC-HCC model: a combination of glybican-3 with other routine parameters improves the diagnostic efficacy in hepatocellular carcinoma. Tumor Biol 2016;37:12571-7. [DOI: 10.1007/s13277-016-5127-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
34 Liu Z, Wu M, Lin D, Li N. Des-gamma-carboxyprothrombin is a favorable biomarker for the early diagnosis of alfa-fetoprotein-negative hepatitis B virus-related hepatocellular carcinoma. J Int Med Res 2020;48:300060520902575. [PMID: 32054358 DOI: 10.1177/0300060520902575] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Rudnick SR, Russo MW. Liver transplantation beyond or downstaging within the Milan criteria for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2018;12:265-75. [PMID: 29231769 DOI: 10.1080/17474124.2018.1417035] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.2] [Reference Citation Analysis]
36 Shen P, Si J, Li QW, Qu LL, Li LR, Yan XL, Ji GZ. Human des-γ-carboxy prothrombin: Cloning, expression and monoclonal antibody preparation. Shijie Huaren Xiaohua Zazhi 2013; 21(35): 3932-3939 [DOI: 10.11569/wcjd.v21.i35.3932] [Reference Citation Analysis]
37 Chan SL, Chan AW. Development of Serum DHCR24 Antibody as a Marker for Hepatocellular Carcinoma: The End of the Beginning. EBioMedicine 2015;2:497-8. [PMID: 26288814 DOI: 10.1016/j.ebiom.2015.05.020] [Reference Citation Analysis]
38 Liu X, Cui D, Li Y, Liu Y, Liu G, Liu L. Multiple “Omics” data-based biomarker screening for hepatocellular carcinoma diagnosis. WJG 2019;25:4199-212. [DOI: 10.3748/wjg.v25.i29.4199] [Cited by in CrossRef: 3] [Article Influence: 1.0] [Reference Citation Analysis]
39 Piñero F, Dirchwolf M, Pessôa MG. Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment. Cells 2020;9:E1370. [PMID: 32492896 DOI: 10.3390/cells9061370] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
40 Yi X, Yu S, Bao Y. Alpha-fetoprotein-L3 in hepatocellular carcinoma: a meta-analysis. Clin Chim Acta. 2013;425:212-220. [PMID: 23954771 DOI: 10.1016/j.cca.2013.08.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
41 Abu El Makarem M. An overview of biomarkers for the diagnosis of hepatocellular carcinoma. Hepat Mon 2012;12:e6122. [PMID: 23162601 DOI: 10.5812/hepatmon.6122] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
42 Huang TS, Shyu YC, Turner R, Chen HY, Chen PJ. Diagnostic performance of alpha-fetoprotein, lens culinaris agglutinin-reactive alpha-fetoprotein, des-gamma carboxyprothrombin, and glypican-3 for the detection of hepatocellular carcinoma: a systematic review and meta-analysis protocol. Syst Rev. 2013;2:37. [PMID: 23738605 DOI: 10.1186/2046-4053-2-37] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
43 Na K, Jeong SK, Lee MJ, Cho SY, Kim SA, Lee MJ, Song SY, Kim H, Kim KS, Lee HW. Human liver carboxylesterase 1 outperforms alpha-fetoprotein as biomarker to discriminate hepatocellular carcinoma from other liver diseases in Korean patients. Int J Cancer. 2013;133:408-415. [PMID: 23319432 DOI: 10.1002/ijc.28020] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
44 Kelley RK, Nimeiri HS, Munster PN, Vergo MT, Huang Y, Li CM, Hwang J, Mulcahy MF, Yeh BM, Kuhn P. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates. Ann Oncol. 2013;24:1900-1907. [PMID: 23519998 DOI: 10.1093/annonc/mdt109] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 4.2] [Reference Citation Analysis]
45 Sterling RK, Wright EC, Morgan TR, Seeff LB, Hoefs JC, Di Bisceglie AM, Dienstag JL, Lok AS. Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol. 2012;107:64-74. [PMID: 21931376 DOI: 10.1038/ajg.2011.312] [Cited by in Crossref: 74] [Cited by in F6Publishing: 65] [Article Influence: 6.7] [Reference Citation Analysis]
46 Nguyen K, Jimenez M, Moghadam N, Wu C, Farid A, Grotts J, Elashoff D, Choi G, Durazo FA, El-Kabany MM. Decrease of Alpha-fetoprotein in Patients with Cirrhosis Treated with Direct-acting Antivirals. J Clin Transl Hepatol. 2017;5:43-49. [PMID: 28507926 DOI: 10.14218/jcth.2016.00057] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
47 Shariff MI, Cox IJ, Gomaa AI, Khan SA, Gedroyc W, Taylor-robinson SD. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Review of Gastroenterology & Hepatology 2014;3:353-67. [DOI: 10.1586/egh.09.35] [Cited by in Crossref: 197] [Cited by in F6Publishing: 194] [Article Influence: 24.6] [Reference Citation Analysis]
48 Inoue T, Tanaka Y. Novel biomarkers for the management of chronic hepatitis B. Clin Mol Hepatol 2020;26:261-79. [PMID: 32536045 DOI: 10.3350/cmh.2020.0032] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
49 Gupta M, Gabriel H, Miller FH. Role of Imaging in Surveillance and Diagnosis of Hepatocellular Carcinoma. Gastroenterology Clinics of North America 2018;47:585-602. [DOI: 10.1016/j.gtc.2018.04.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
50 Sherman M. Histological diagnosis of early hepatocellular carcinoma. Hepatology 2011;53:1427-9. [PMID: 21452287 DOI: 10.1002/hep.24332] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
51 Lai Q, Melandro F, Pinheiro RS, Donfrancesco A, Fadel BA, Levi Sandri GB, Rossi M, Berloco PB, Frattaroli FM. Alpha-fetoprotein and novel tumor biomarkers as predictors of hepatocellular carcinoma recurrence after surgery: a brilliant star raises again. Int J Hepatol. 2012;2012:893103. [PMID: 22792474 DOI: 10.1155/2012/893103] [Cited by in Crossref: 23] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
52 Kiriyama S, Uchiyama K, Ueno M, Ozawa S, Hayami S, Tani M, Yamaue H. Triple positive tumor markers for hepatocellular carcinoma are useful predictors of poor survival. Ann Surg. 2011;254:984-991. [PMID: 21606837 DOI: 10.1097/sla.0b013e3182215016] [Cited by in Crossref: 36] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
53 Sharma B, Srinivasan R, Chawla YK, Kapil S, Saini N, Singla B, Chakraborthy A, Kalra N, Duseja A, Dhiman RK. Clinical utility of prothrombin induced by vitamin K absence in the detection of hepatocellular carcinoma in Indian population. Hepatol Int. 2010;4:569-576. [PMID: 21063479 DOI: 10.1007/s12072-010-9186-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
54 Okajima W, Komatsu S, Ichikawa D, Miyamae M, Kawaguchi T, Hirajima S, Ohashi T, Imamura T, Kiuchi J, Arita T, Konishi H, Shiozaki A, Moriumura R, Ikoma H, Okamoto K, Taniguchi H, Itoh Y, Otsuji E. Circulating microRNA profiles in plasma: Identification of miR-224 as a novel diagnostic biomarker in hepatocellular carcinoma independent of hepatic function. Oncotarget. 2016;7:53820-53836. [PMID: 27462777 DOI: 10.18632/oncotarget.10781] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 8.3] [Reference Citation Analysis]
55 Wu CS, Lee TY, Chou RH, Yen CJ, Huang WC, Wu CY, Yu YL. Development of a highly sensitive glycan microarray for quantifying AFP-L3 for early prediction of hepatitis B virus-related hepatocellular carcinoma. PLoS One. 2014;9:e99959. [PMID: 24927126 DOI: 10.1371/journal.pone.0099959] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
56 Lee HA, Lee YR, Lee YS, Jung YK, Kim JH, An H, Yim HJ, Jeen YT, Yeon JE, Byun KS, Seo YS. Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein improves diagnostic accuracy for hepatocellular carcinoma. World J Gastroenterol 2021; 27(28): 4687-4696 [PMID: 34366629 DOI: 10.3748/wjg.v27.i28.4687] [Reference Citation Analysis]
57 Li C, Zhang Z, Zhang P, Liu J. Diagnostic accuracy of des-gamma-carboxy prothrombin versus α-fetoprotein for hepatocellular carcinoma: A systematic review. Hepatol Res. 2014;44:E11-E25. [PMID: 23834468 DOI: 10.1111/hepr.12201] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 4.8] [Reference Citation Analysis]
58 Colli A, Nadarevic T, Miletic D, Giljaca V, Fraquelli M, Štimac D, Casazza G. Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev 2021;4:CD013346. [PMID: 33855699 DOI: 10.1002/14651858.CD013346.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
59 Hu B, Tian X, Sun J, Meng X. Evaluation of individual and combined applications of serum biomarkers for diagnosis of hepatocellular carcinoma: a meta-analysis. Int J Mol Sci. 2013;14:23559-23580. [PMID: 24317431 DOI: 10.3390/ijms141223559] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 5.0] [Reference Citation Analysis]
60 Cervena K, Vodicka P, Vymetalkova V. Diagnostic and prognostic impact of cell-free DNA in human cancers: Systematic review. Mutation Research/Reviews in Mutation Research 2019;781:100-29. [DOI: 10.1016/j.mrrev.2019.05.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
61 Singal AG, Haaland B, Parikh ND, Ozbay AB, Kirshner C, Chakankar S, Porter K, Chhatwal J, Ayer T. Comparison of a multitarget blood test to ultrasound and alpha-fetoprotein for hepatocellular carcinoma surveillance: Results of a network meta-analysis. Hepatol Commun 2022. [PMID: 35945907 DOI: 10.1002/hep4.2045] [Reference Citation Analysis]
62 Yazici C, Niemeyer DJ, Iannitti DA, Russo MW. Hepatocellular carcinoma and cholangiocarcinoma: an update. Expert Review of Gastroenterology & Hepatology 2013;8:63-82. [DOI: 10.1586/17474124.2014.852468] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
63 Zhang J, Chen G, Zhang P, Zhang J, Li X, Gan D, Cao X, Han M, Du H, Ye Y. The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis. PLoS One. 2020;15:e0228857. [PMID: 32053643 DOI: 10.1371/journal.pone.0228857] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 10.5] [Reference Citation Analysis]
64 Conti F, Dall'Agata M, Gramenzi A, Biselli M. Biomarkers for the early diagnosis of bacterial infection and the surveillance of hepatocellular carcinoma in cirrhosis. Biomark Med 2015;9:1343-51. [PMID: 26580585 DOI: 10.2217/bmm.15.100] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
65 Okajima W, Komatsu S, Ichikawa D, Miyamae M, Ohashi T, Imamura T, Kiuchi J, Nishibeppu K, Arita T, Konishi H, Shiozaki A, Morimura R, Ikoma H, Okamoto K, Otsuji E. Liquid biopsy in patients with hepatocellular carcinoma: Circulating tumor cells and cell-free nucleic acids. World J Gastroenterol 2017; 23(31): 5650-5668 [PMID: 28883691 DOI: 10.3748/wjg.v23.i31.5650] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 49] [Article Influence: 10.0] [Reference Citation Analysis]
66 Zhao Y, Gao Q, Pei L, Wang C, Jin L, Liao F. Current Status and Future Prospects of Biomarkers in the Diagnosis of Hepatocellular Carcinoma. Int J Biol Markers 2017;32:361-9. [DOI: 10.5301/ijbm.5000299] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
67 Sun S, Poon RT, Lee NP, Yeung C, Chan KL, Ng IO, Day PJ, Luk JM. Proteomics of hepatocellular carcinoma: serum vimentin as a surrogate marker for small tumors (<or=2 cm). J Proteome Res 2010;9:1923-30. [PMID: 20121168 DOI: 10.1021/pr901085z] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 3.9] [Reference Citation Analysis]
68 Qu KZ, Zhang K, Ma W, Li H, Wang X, Zhang X, Giles F, Lai M, Afdhal NH, Albitar M. Ubiquitin-proteasome profiling for enhanced detection of hepatocellular carcinoma in patients with chronic liver disease: Serum proteasomes and hepatocellular cancer. Journal of Gastroenterology and Hepatology 2011;26:751-8. [DOI: 10.1111/j.1440-1746.2010.06491.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
69 Degasperi E, Perbellini R, D'Ambrosio R, Uceda Renteria SC, Ceriotti F, Perego A, Orsini C, Borghi M, Iavarone M, Bruccoleri M, Rimondi A, De Silvestri A, Sangiovanni A, Lampertico P. Prothrombin induced by vitamin K absence or antagonist-II and alpha foetoprotein to predict development of hepatocellular carcinoma in Caucasian patients with hepatitis C-related cirrhosis treated with direct-acting antiviral agents. Aliment Pharmacol Ther 2021. [PMID: 34738664 DOI: 10.1111/apt.16685] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
70 Han C, Gao L, Zhao L, Sheng Q, Zhang C, An Z, Xia T, Ding Y, Wang J, Bai H, Dou X. Immunohistochemistry Detects Increased Expression of Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) in Early-Stage Hepatocellular Carcinoma. Med Sci Monit. 2018;24:7414-7423. [PMID: 30328412 DOI: 10.12659/msm.910738] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
71 Han C, Gao L, Bai H, Dou X. Identification of a role for serum aldo-keto reductase family 1 member B10 in early detection of hepatocellular carcinoma. Oncol Lett 2018;16:7123-30. [PMID: 30546447 DOI: 10.3892/ol.2018.9547] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
72 Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer. 2013;13:123-135. [PMID: 23344543 DOI: 10.1038/nrc3449] [Cited by in Crossref: 505] [Cited by in F6Publishing: 481] [Article Influence: 56.1] [Reference Citation Analysis]
73 Muirhead LJ, Kinross J, FitzMaurice TS, Takats Z, Darzi A, Nicholson JK. Surgical systems biology and personalized longitudinal phenotyping in critical care. Per Med 2012;9:593-608. [PMID: 29768802 DOI: 10.2217/pme.12.70] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
74 Hanif H, Ali MJ, Susheela AT, Khan IW, Luna-Cuadros MA, Khan MM, Lau DTY. Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma. World J Gastroenterol 2022; 28(2): 216-229 [DOI: 10.3748/wjg.v28.i2.216] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
75 Wang X, Zhang Y, Yang N, He H, Tao X, Kou C, Jiang J. Evaluation of the Combined Application of AFP, AFP-L3%, and DCP for Hepatocellular Carcinoma Diagnosis: A Meta-analysis. Biomed Res Int 2020;2020:5087643. [PMID: 33015170 DOI: 10.1155/2020/5087643] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
76 Lou J, Zhang L, Lv S, Zhang C, Jiang S. Biomarkers for Hepatocellular Carcinoma. Biomark Cancer. 2017;9:1-9. [PMID: 28469485 DOI: 10.1177/1179299x16684640] [Cited by in Crossref: 61] [Cited by in F6Publishing: 41] [Article Influence: 12.2] [Reference Citation Analysis]
77 Stefaniuk P, Cianciara J, Wiercinska-Drapalo A. Present and future possibilities for early diagnosis of hepatocellular carcinoma. World J Gastroenterol 2010; 16(4): 418-424 [PMID: 20101765 DOI: 10.3748/wjg.v16.i4.418] [Cited by in CrossRef: 116] [Cited by in F6Publishing: 118] [Article Influence: 9.7] [Reference Citation Analysis]
78 Li D, Satomura S. Biomarkers for Hepatocellular Carcinoma (HCC): An Update. Adv Exp Med Biol 2015;867:179-93. [PMID: 26530367 DOI: 10.1007/978-94-017-7215-0_12] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
79 Canale M, Ulivi P, Foschi FG, Scarpi E, De Matteis S, Donati G, Ercolani G, Scartozzi M, Faloppi L, Passardi A, Tamburini E, Valgiusti M, Marisi G, Frassineti GL, Casadei Gardini A. Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma. Critical Reviews in Oncology/Hematology 2018;129:44-53. [DOI: 10.1016/j.critrevonc.2018.06.017] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
80 Dadfar SMM, Sekula-Neuner S, Trouillet V, Liu HY, Kumar R, Powell AK, Hirtz M. Evaluation of click chemistry microarrays for immunosensing of alpha-fetoprotein (AFP). Beilstein J Nanotechnol 2019;10:2505-15. [PMID: 31921529 DOI: 10.3762/bjnano.10.241] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Sherman M. Primary Malignant Neoplasms of the Liver. In: Dooley JS, Lok ASF, Burroughs AK, Heathcote EJ, editors. Sherlock's Diseases of the Liver and Biliary System. Oxford: Wiley-Blackwell; 2011. pp. 681-703. [DOI: 10.1002/9781444341294.ch35] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
82 Hanaoka T, Sato S, Tobita H, Miyake T, Ishihara S, Akagi S, Amano Y, Kinoshita Y. Clinical significance of the highly sensitive fucosylated fraction of α-fetoprotein in patients with chronic liver disease. J Gastroenterol Hepatol. 2011;26:739-744. [PMID: 21083609 DOI: 10.1111/j.1440-1746.2010.06585.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
83 Bachtiar I, Kheng V, Wibowo GA, Gani RA, Hasan I, Sanityoso A, Budhihusodo U, Lelosutan SA, Martamala R, Achwan WA. Alpha-1-acid glycoprotein as potential biomarker for alpha-fetoprotein-low hepatocellular carcinoma. BMC Res Notes. 2010;3:319. [PMID: 21092242 DOI: 10.1186/1756-0500-3-319] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
84 Waidely E, Al-Yuobi AR, Bashammakh AS, El-Shahawi MS, Leblanc RM. Serum protein biomarkers relevant to hepatocellular carcinoma and their detection. Analyst. 2016;141:36-44. [PMID: 26606739 DOI: 10.1039/c5an01884f] [Cited by in Crossref: 40] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]